Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Noven Files Patent Infringement Lawsuit against Alvogen

Noven Pharmaceuticals,Inc.
Posted on: 07 Nov 17

Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court of Delaware against Alvogen, Inc. and Alvogen Pine Brook, LLC. (collectively, “Alvogen”) for patent infringement.

Alvogen is seeking approval to market and sell a generic version of Minivelle® (estradiol transdermal system) prior to the expiration of two of Noven’s Orange Book listed patents (U.S. Patent Nos. 9724310 and 9730900). The lawsuit reflects Noven’s commitment to vigorously enforce its intellectual property rights against infringement.

Regarding this filing, Michael Greene, Noven’s General Counsel, stated, “Minivelle® is Noven’s premier commercialized product. We are confident in the strength of our patent position and it is our intent to aggressively protect Minivelle® and our intellectual property. Any launch by Alvogen of a generic version of Minivelle® prior to resolution of the patent litigation should be considered an `at-risk' launch, which could subject Alvogen to significant damages among other remedies.”

About Noven

Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Noven’s mission is to develop and offer pharmaceutical products that meaningfully benefit patients around the world, with a commitment to advancing patient care through transdermal drug delivery. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., serving as Hisamitsu’s U.S. platform in prescription pharmaceuticals, and helping Hisamitsu bring the benefits of patch therapy to the world. For more information about Noven, visit www.noven.com. For information about Hisamitsu, visit www.hisamitsu.co.jp/english.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171107006291/en/

Business Wire
www.businesswire.com

Last updated on: 07/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.